[HTML][HTML] Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors
V Leko, SA Rosenberg - Cancer Cell, 2020 - cell.com
Cancer elimination in humans can be achieved with immunotherapy that relies on T
lymphocyte-mediated recognition of tumor antigens. Several types of these antigens have …
lymphocyte-mediated recognition of tumor antigens. Several types of these antigens have …
Neoantigens: promising targets for cancer therapy
Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma
CD8+ T cell reactivity towards tumor mutation-derived neoantigens is widely believed to
facilitate the antitumor immunity induced by immune checkpoint blockade (ICB). Here we …
facilitate the antitumor immunity induced by immune checkpoint blockade (ICB). Here we …
Immune-checkpoint inhibitor resistance in cancer treatment: current progress and future directions
C Zhang, C Zhang, H Wang - Cancer letters, 2023 - Elsevier
Cancer treatment has been advanced with the advent of immune checkpoint inhibitors (ICIs)
exemplified by anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed …
exemplified by anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed …
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
Z Pang, M Lu, Y Zhang, Y Gao, J Bai, J Gu, L Xie… - Biomarker …, 2023 - Springer
Adoptive cell therapy using T cell receptor-engineered T cells (TCR-T) is a promising
approach for cancer therapy with an expectation of no significant side effects. In the human …
approach for cancer therapy with an expectation of no significant side effects. In the human …
A roadmap toward the definition of actionable tumor-specific antigens
R Minati, C Perreault, P Thibault - Frontiers in Immunology, 2020 - frontiersin.org
The search for tumor-specific antigens (TSAs) has considerably accelerated during the past
decade due to the improvement of proteogenomic detection methods. This provides new …
decade due to the improvement of proteogenomic detection methods. This provides new …
Facts and hopes for immunotherapy in renal cell carcinoma
Immunotherapy has made a significant impact in many tumors, including renal cell
carcinoma (RCC). RCC has been known to be immunoresponsive since the cytokine era of …
carcinoma (RCC). RCC has been known to be immunoresponsive since the cytokine era of …
Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens
MM Wolf, WK Rathmell, AA de Cubas - Nature Reviews Nephrology, 2023 - nature.com
Renal cell carcinoma (RCC) comprises a group of malignancies arising from the kidney with
unique tumour-specific antigen (TSA) signatures that can trigger cytotoxic immunity. Two …
unique tumour-specific antigen (TSA) signatures that can trigger cytotoxic immunity. Two …
Biomarkers for immune checkpoint inhibitors in renal cell carcinoma
Immune checkpoint inhibitor (ICI) therapy has revolutionized renal cell carcinoma treatment.
Patients previously thought to be palliative now occasionally achieve complete cures from …
Patients previously thought to be palliative now occasionally achieve complete cures from …
Inflammatory networks in renal cell carcinoma
Simple Summary Inflammation is an important hallmark of advanced renal cell carcinoma
and plays a pivotal role in tumor progression, metastasis, and anti-cancer resistance …
and plays a pivotal role in tumor progression, metastasis, and anti-cancer resistance …